Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know

By Zacks Investment ResearchStock MarketsMar 24, 2020 05:45AM ET
www.investing.com/analysis/regeneron-regn-stock-sinks-as-market-gains-what-you-should-know-200518717
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
By Zacks Investment Research   |  Mar 24, 2020 05:45AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
US500
+0.01%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
DJI
-0.43%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Regeneron (REGN) closed at $449.53 in the latest trading session, marking a -1.34% move from the prior day. This move lagged the S&P 500's daily gain of 9.38%. At the same time, the Dow added 11.37%, and the tech-heavy Nasdaq gained 8.12%.

Coming into today, shares of the biopharmaceutical company had gained 7.11% in the past month. In that same time, the Medical sector lost 27.39%, while the S&P 500 lost 32.94%.

Investors will be hoping for strength from REGN as it approaches its next earnings release. In that report, analysts expect REGN to post earnings of $6.29 per share. This would mark year-over-year growth of 41.35%. Our most recent consensus estimate is calling for quarterly revenue of $2.13 billion, up 24.22% from the year-ago period.

REGN's full-year Zacks Consensus Estimates are calling for earnings of $29.21 per share and revenue of $8.90 billion. These results would represent year-over-year changes of +18.4% and +13.15%, respectively.

Investors might also notice recent changes to analyst estimates for REGN. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 6.09% higher within the past month. REGN is holding a Zacks Rank of #1 (Strong Buy) right now.

Investors should also note REGN's current valuation metrics, including its Forward P/E ratio of 15.6. This represents a discount compared to its industry's average Forward P/E of 25.06.

It is also worth noting that REGN currently has a PEG ratio of 0.89. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.41 based on yesterday's closing prices.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 63, which puts it in the top 25% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow REGN in the coming trading sessions, be sure to utilize Zacks.com.



Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Original post

Zacks Investment Research

Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
 

Related Articles

Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email